Reproductive Health

News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.

The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.

The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.

Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.

The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.

Androvia LifeSciences has developed a predictive biomarker test that some clinicians are using to determine a man's fertility.